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Abstract
For efficient prevention of viral infections and cross protection, simultaneous targeting of multiple viral epitopes is a
powerful strategy. Llama heavy chain antibody fragments (VHH) against the trimeric envelope proteins of Respiratory
Syncytial Virus (Fusion protein), Rabies virus (Glycoprotein) and H5N1 Influenza (Hemagglutinin 5) were selected from llama
derived immune libraries by phage display. Neutralizing VHH recognizing different epitopes in the receptor binding sites on
the spikes with affinities in the low nanomolar range were identified for all the three viruses by viral neutralization assays. By
fusion of VHH with variable linker lengths, multimeric constructs were made that improved neutralization potencies up to
4,000-fold for RSV, 1,500-fold for Rabies virus and 75-fold for Influenza H5N1. The potencies of the VHH constructs were
similar or better than best performing monoclonal antibodies. The cross protection capacity against different viral strains
was also improved for all three viruses, both by multivalent (two or three identical VHH) and biparatopic (two different VHH)
constructs. By combining a VHH neutralizing RSV subtype A, but not subtype B with a poorly neutralizing VHH with high
affinity for subtype B, a biparatopic construct was made with low nanomolar neutralizing potency against both subtypes.
Trivalent anti-H5N1 VHH neutralized both Influenza H5N1 clade1 and 2 in a pseudotype assay and was very potent in
neutralizing the NIBRG-14 Influenza H5N1 strain with IC50 of 9 picomolar. Bivalent and biparatopic constructs against Rabies
virus cross neutralized both 10 different Genotype 1 strains and Genotype 5. The results show that multimerization of VHH
fragments targeting multiple epitopes on a viral trimeric spike protein is a powerful tool for anti-viral therapy to achieve
‘‘best-in-class’’ and broader neutralization capacity.
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Introduction
Viruses are a continuous threat to humans, exemplified by the
recent appearance of the 2009 pandemic H1N1 influenza virus.
Because of the genetic variability of RNA viruses, they are difficult
to control by prophylactic or anti-viral therapy. Vaccines need to
induce a neutralizing immune response against highly conserved
epitopes to be effective, but very limited success has been obtained
so far. Several very potent anti-viral compounds have been
developed for treatment of for instance HIV, Hepatitis B and
influenza infections, but their use have rapidly been followed by
the appearance of drug-induced escape mutants [1,2].
For many enveloped viruses, entry into target cell depends on
fusion of the viral and cell membranes, driven by the interaction of
viral glycoproteins with the target cell membrane. In this study, we
evaluated three different negative strand RNA viruses with
trimeric envelope proteins, Fusion protein (F protein) of
Respiratory Syncytial Virus (RSV), H5 hemagglutinin of H5N1
avian Influenza and Rabies glycoprotein (G protein). RSV is the
major cause of lower respiratory infection and hospitalization of
infants and young children and the current prophylactic treatment
with the monoclonal antibody Synagis is restricted to infants that
are premature or have heart or lung disease. Influenza H5N1
(avian flu) is highly pathogenic and virulent and is spread from
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There is no current cure, but vaccines and neutralizing antibodies
are being developed. Rabies is also a virus spread from animals to
humans and causes acute encephalitis which is fatal if post-
exposure prophylaxis is not administered before the virus has
infected the brain. All three viruses cause severe infections in
humans and even though neutralizing antibodies are available for
Rabies and RSV, there is a need for alternative and improved
antiviral therapy.
Llama-derived single domain VHHs have proven to be
powerful viral neutralizers [3,4,5,6]. The single chain nature of
the VHHs allows construction and production of multimeric
molecules using the same or different VHH building blocks [7,8].
Single domain molecules (VHH) are the antigen binding, variable
part of heavy chain only antibodies. These heavy-chain antibodies
are devoid of the light chain and found in members of the
Camelidae family, such as the llama [9]. VHHs are small (12–
15 kDa), stable molecules with improved solubility and similar
affinities as conventional antibodies [10]. These properties make
them promising molecules for prophylactic and therapeutic
purposes.
In this study, we demonstrate that the formatting flexibility of
the VHH allows the generation of anti-viral molecules with low
picomolar neutralizing potencies, up to 4,000-fold better than the
monovalent VHH, and broadened neutralizing activities, likely
overcoming the chance of virus escaping neutralization. The latter
improvement was obtained by either fusing VHH recognizing
different epitopes, but also by fusing multiple copies of the same
VHH. Similar results were obtained with VHHs against the
trimeric spike proteins of all three viruses.
These data demonstrate the general applicability of VHHs for
construction of highly potent anti-viral molecules for treatment of
viral infections.
Results
Isolation of viral spike protein specific VHH
Two llamas per viral target were successfully immunized with
the following antigens; RSV FTM- protein, which is a recombinant
trimeric membrane anchor less form of the fusion protein of
human Respiratory Syncytial Virus (Long strain, subgroup A),
recombinant trimeric H5N1 Hemagglutinin (H5, A/Vietnam/
1203/2004) and Inactivated Rabies Vaccine Me ´rieux HDCV
(genotype 1, Wistar strain of the Pitman Moore virus).
Selections were performed using recombinant RSV FTM-
protein, recombinant H5 Hemagglutinin and Rabies genotype 1,
PV glycoprotein glycoprotein. Binding phage were eluted from the
antigen by unspecific or competitive elution using an excess of viral
neutralizing antibodies for RSV (Synagis) and Rabies (Mab 8-2).
After two rounds of selections, individual clones were isolated,
VHH were produced, purified and screened for binding to the
viral antigens in ELISA and competition with monoclonal
antibodies or in the case of Influenza H5N1, the sialylglycoprotein
fetuin. For RSV, 188 clones were investigated for binding to the
FTM- protein revealing that 79% were interacting. Only 30%
binders were identified for H5 hemagglutinin, while 50% binders
were identified for Rabies G protein. The binding clones were
tested for competition with the antibodies (Synagis or mAb 8-2) or
fetuin and for all the viral targets competitors were identified that
were sequenced and further analyzed for neutralization properties.
By fusing RSV specific VHH, a total of 3 bivalent and 4
biparatopic (i.e bispecific) constructs were made. Two bivalent and
two trivalent Influenza H5N1 constructs and four bivalent and
four biparatopic anti-rabies VHH constructs were made. The
linker lengths (Gly4/Ser) were between 9 and 35. The production
yields for the multimeric constructs were between 0.5 mg/L to
1 mg/L after IMAC purification as compared to monovalent
VHH, with 3–10 fold higher yields.
Neutralization and cross-protection of RSV by VHH
Based on the screenings of the selected clones in binding ELISA
and competition assays, twelve purified VHHs were tested in an in
vitro micro-neutralization assay for neutralization of the RSV Long
strain (subgroup A). Two of the VHH (RSV-D3 and RSV-C4)
neutralized RSV Long strain. RSV-D3 was the most potent with
an IC50 of 250 nM (Fig. 1A). IC50 for both Synagis Mab and Fab
were in the range of what has previously been reported [11]. RSV-
D3 and RSV-C4 VHH did not have any neutralization effect on
RSV B1 strain (subgroup B). However, there was a minor effect by
monovalent RSV-E4, which did not neutralize the RSV Long
strain (data not shown).
For further characterization of the neutralizing VHHs, ELISA
based competition assays were performed on immobilized RSV
FTM- protein, using Fab fragments derived from two different
neutralizing monoclonal antibodies, Synagis (humanized version
of mouse Mab 1129, recognizing antigenic site II) and 101F
(recognizing antigenic site IV–VI), binding different epitopes on
the F protein [12,13,14]. VHHs RSV-D3 and RSV-C4 competed
with Synagis Fab and RSV-E4 competed with 101F Fab for
binding to RSV FTM- protein (Fig. 1B and C). RSV-D3 and RSV-
C4 also showed some competition at high concentrations (mM)
with 101F Fab, indicating the epitope recognized by these VHH is
overlapping to some degree, but most binding parts are in the
antigenic site II (Fig. 1C). These results were confirmed in
independent experiments using both the Fabs and the monoclonal
antibodies of Synagis and 101F (data not shown). The Fab
competitions were also confirmed on immobilized inactivated
RSV (data not shown).
The epitopes recognized by VHHs directed against RSV F
protein were further investigated by testing their reactivity in
ELISA with previously described RSV escape mutants [15].
Absorbance results were normalized for reactivity on the reference
virus strain (Long wild type) as well as on the control RSV-C7
(RSV FTM- protein binder, but non-competitor). VHH RSV-D3
and RSV-C4 were found to be sensitive to typical mutations in
antigenic site II, confirming the competition pattern with Synagis,
while VHH RSV-E4 was sensitive to mutations in the antigenic
site IV–VI, confirming the competition results with 101F (Fig. 2).
RSV-C4 and RSV-D3 bound to the same mutants with some
small differences, possibly due to differences in affinity or
recognition of overlapping epitopes. RSV-D3 showed a weak
binding to RRA3, a double mutant with changes in both site II
and IV–VI.
Affinities of the monovalent VHHs selected against RSV were
measured by Surface Plasmon Resonance and were in the low
nanomolar range (Table 1). VHH RSV-E4, bound to RSV F
protein with an affinity (KD) of 0.45 nM, which was slightly better
than the Mab Synagis with a KD of 0.64 nM and about 15-fold
better than the Fab fragment of Synagis.
Next, we investigated if linking two identical RSV-D3 VHHs
(bivalent RSV-D3) with flexible Gly4/Ser linkers of different
lengths could enhance the neutralization potency of VHHs.
Remarkably, bivalent RSV-D3 VHHs could neutralize RSV Long
strain about 4000-fold better than the monovalent RSV-D3 VHH.
All three bivalent VHH neutralized the RSV Long strain better
then Synagis Mab and Synagis Fab with IC50’s of approximately
0.1 nM compared to 6.5 nM for Synagis Mab and 1.3 mM for
Synagis Fab (Fig. 1D and Table 2). There was no significant
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bivalent RSV-D3 constructs with different linker lengths (15, 25 or
35 GS linkers). All experiments were run two independent times
comparing with the controls Synagis Fab or mAb and the
monovalent RSV-D3 showing the same fold difference in
neutralization as compared to the monovalent RSV-D3.
To target two different epitopes on the RSV F protein,
biparatopic VHH construct containing two different VHHs were
generated with linker lengths of 9, 15 or 25 GS residues. The
biparatopic VHH RSV-D3/E4 contained RSV-D3 and RSV-E4
VHH, which respectively recognized the Synagis-like epitope and
the 101F-like RSV epitope. The biparatopic constructs were
investigated for cross neutralization of both RSV Long strain and
RSV B1 strain.
The two biparatopic VHHs, RSV-D3/E4 VHH having linkers
of either 9 or 15 residues, had comparable neutralization potency
as the Synagis Mab (IC50 of 6.5 nM) and were about 40-fold better
in neutralizing the Long strain (subtype A) and RSV-D3/E4(9GS)
was more than 500-fold better for the B1 strain as compared to the
monovalent VHHs. There was no significant difference in
neutralization potency of the RSV Long strain between the two
biparatopic VHHs RSV-D3/E4(9GS) and RSV-D3/E4(15GS)
(IC50 of 6 nM and 5.2 nM, respectively) (Table 2). The
biparatopic construct with a 25 GS linker had an IC50 of 18 nM
for RSV Long strain, about 3-fold lower than the constructs with
the shorter linkers, 9 or 15 GS. The biparatopic constructs were
not as potent in neutralization of RSV Long strain as the bivalent
RSV-D3.
We further investigated if neutralization of the RSV B1 strain
was achieved with the biparatopic constructs and if the order of
the VHH made a difference for the potency. The biparatopic
constructs with RSV-D3 in the N-terminal and RSV-E4 in the C-
terminal position and a linker length of 9 GS (RSV-D3/E4) was
about 15-fold more potent in neutralizing the RSV B1 strain as
compared to the fusion protein with the VHH in the opposite
direction (RSVE4/D3), IC50 of 1.8 nM compared to 29 nM
(Table 2). There was a slightly better neutralizing effect when
combining RSV-E4 (5 nM) and RSV-D3 (5 nM) in an equimolar
Figure 1. Microneutralization and antibody competition of RSV-specific VHH. Monovalent VHH neutralizing RSV Long strain, subtype A.
Neutralization is expressed in percentage as compared to controls with irrelevant VHH, plotted against the concentrations of VHH in molar (M) (A).
Anti-RSV VHH competing with 3 nM Synagis Fab for binding to immobilized RSV F protein, presented in percentage of competition as compared to
controls with no VHH or irrelevant VHH. NR is an irrelevant control VHH against H5N1. Binding of Synagis Fab was detected as described in the text
and absorbance was read at 450 nm (B). Anti-RSV VHH competing with 3 nM 101F Fab for binding to immobilized RSV F protein, presented in
percentage of competition as compared to controls with no VHH or irrelevant VHH. NR is an irrelevant control VHH against H5N1. Binding of 101F Fab
was detected as described in the text and absorbance was read at 450 nm. (C). Bivalent RSV-D3 constructs with linker lengths from 15-35GS
neutralizing RSV Long strain, subtype A. Neutralization is expressed in percentage, as compared to controls with irrelevant VHH and plotted against
the concentrations of VHH in molar (M) (D). All experiments were repeated two times and the figure represents one experiment.
doi:10.1371/journal.pone.0017665.g001
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comparable to the potency of the biparatopic constructs.
Neutralization and cross clade protection of VHH against
Influenza H5N1
The neutralizing capacity of VHH against Influenza H5 A/
Vietnam/1203/04 (clade 1) viruses, were evaluated in the
MLV(H5) pseudotyped neutralization assay [16]. Two of 28
tested VHHs (Infl-C8 and Infl-B12), selected on A/Vietnam/
1194/04, neutralized the pseudotyped A/Vietnam/1203/04 virus
(Fig. 3A). The neutralization was run in duplicates and the graph
represents the geometric means. Both VHH competed with
sialylglycoprotein fetuin, which binds the receptor binding site of
hemagglutinin 5 (Fig. 3B). The VHHs had affinities to hemagglu-
tinin 5 of clade 1, A/Vietnam/1194/04 in the nanomolar range
(9.9 nM and 30 nM for Infl-C8 and Infl-B12, respectively)
(Table 1). VHHs Infl-C8 and Infl-B12 neutralized A/Vietnam/
1194/04 as effectively as A/Vietnam/1203/04. No synergistic
effect was observed when mixing the neutralizing VHH in an
equimolar ratio, only an additive effect (data not shown).
Figure 2. Binding of VHH in ELISA to RSV escape mutants using HEp-2 cells infected with the indicated viral strains as substrate.
Absorbance results were normalized for reactivity on the reference virus strain (Long wild type) strain as well as on the control VHH RSV-C7 (RSV
binder, but non-competitor to Synagis and 101F). (&).75% reactivity compared to RSV-C7, (&) 50–75% reactivity compared to RSV-C7, (&) 50–25%
reactivity compared to RSV-C7, (%) ,25% reactivity compared to RSV-C7. Binding was confirmed in two independent experiments.
doi:10.1371/journal.pone.0017665.g002
Table 1. Affinities of monovalent VHH against recombinant
Influenza H5 and RSV F protein measured by Surface Plasmon
Resonance.
sample antigen kon (M
21 s
21) koff (s
21) KD (nM)
a
Infl-C8 Influenza H5 4.99610
5 4.95610
23 9.91
Infl-B12 Influenza H5 2.14610
5 6.45610
23 30.1
RSV-D3 RSV FTM- 9.89610
5 9.14610
23 1.78
RSV-C4 RSV FTM- 1.48610
6 2.64610
23 9.24
RSV-E4 RSV FTM- 4.64610
5 2.09610
24 0.45
Synagis Mab RSV FTM- 2.77610
5 1.78610
24 0.64
Synagis Fab RSV FTM- 1.69610
5 5.05610
24 2.99
aEqulibrium dissociation constant KD (koff/kon), association rate constant kon and
dissociation constant koff determined by Surface Plasmon Resonance.
doi:10.1371/journal.pone.0017665.t001
Table 2. Microneutralization of RSV subtype A and B.
Microneutralization, IC50 (nM)
RSV Long (A) RSV B1 (B)
monovalent VHH
RSV-C4 640 n.d.
b
RSV-D3 4606149
d .1000
RSV-E4 No effect .1000
RSV-D3+RSV-E4 n.d. .1000
Bivalent VHH Potency increase
a
RSV-D3(15GS)2 0.14 3285 103
RSV-D3(25GS)2 0.11 4181 n.d
RSV-D3(35GS)2 0.19 2421 n.d
Biparatopic VHH
RSV-D3/E4(9GS) 6 37 1.8
RSV-D3/E4(15GS) 5.2 43 n.d.
RSV-D3/E4(25GS) 18 12 n.d
RSV-E4/D3(9GS) 100 2 29
Mab/Fab
Synagis Mab 6.5610 200
c 2.1
Synagis Fab 13006990 - n.d.
101F Fab 1500 - 101
aincreased potency against RSV Long (A) compared to the monovalent RSV-D3
VHH.
bnot determined.
cincreased potency compared to Fab.
dSD of two independent experiments with the controls.
doi:10.1371/journal.pone.0017665.t002
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Influenza H5 clade 1 pseudotype strains (A/Vietnam/1203/04
and A/Vietnam/1194/04) and epitope recognition, bivalent and
trivalent constructs were generated, by fusing individual VHH
domains with Gly4/Ser linkers. The majority of the tested bivalent
and trivalent VHH constructs had a significantly higher
neutralizing potency than the corresponding monovalent VHH
against all four clades of H5N1 tested, with the bivalent and
trivalent constructs based on Infl-C8 being the best neutralizers
(Table 3). Bivalent Infl-C8 constructs against H5N1 showed no
difference in neutralization potency for the two clade 1
hemagglutinins A/Vietnam/1194/04 and A/Vietnam/1203/04.
The neutralizing potency of the trivalent Infl-C8 against various
clades of Influenza H5N1 was significantly increased compared to
monovalent VHH against all the H5N1 clades tested. The
trivalent VHH, Infl-C8 with a 10 GS linker had a 75-fold
increased potency compared to the corresponding monovalent
VHH in neutralizing the A/Vietnam clades. Trivalent Infl-C8
with a 20 GS linker had a slightly lower potency than the 10 GS
linker construct (Table 3). All experiments were run in duplicates
and presented as IC50 of the geomeotric mean of the monovalent
VHH. Remarkable is the jump in potency for the bivalent Infl-C8
construct with a 10 GS linker for the clade 2.2 strains, whereas the
same construct with 20GS linker has a somewhat lower
neutralization capacity.
The neutralization potency and cross protection by the bivalent
and trivalent VHH was further confirmed in a microneutralization
assay using the NIBRG-14 Influenza H5N1 strain on MDCK
cells. The potencies for the neutralization was in the picomolar
range (IC50 9 and 3 pM for the bi- and trivalent VHH,
respectively), which is about 1,000-fold more potent than the
previously published monoclonal antibody CR6261 (IC50 of
around 3–4 nM) [17]. No cross-neutralization of PR8 (H1N1) or
X47 (H3N2) virus was observed.
Finally, a hemagglutination inhibition assay (HAI) was per-
formed to investigate if the Infl-C8 constructs sterically blocked the
attachment of Influenza H5N1 virus, NIBRG-14, to chicken
erythrocytes (RBC). The minimal concentration of bivalent and
trivalent Infl-C8 inhibiting hemagglutination of RBC by NIBRG-
14 virus was 2 nM, as compared to the monovalent Infl-C8, which
inhibited hemagglutination at 156 nM.
Neutralization of divergent Lyssavirus genotypes
VHH selected against the Rabies genotype 1, PV glycoprotein,
were examined for cross-neutralization of different genotype 1
lyssaviruses (three laboratory strains and seven street isolates) and
one genotype 5 lyssavirus (European bat lyssavirus-1, EBLV-1).
Human cases of Rabies (.99%) are caused by genotype 1
lyssaviruses [18]. EBLV-1 circulates in certain species of bats
(mainly Eptesicus serotinus) in Europe [19].
In general, VHH which neutralized the prototype CVS-11
strain (genotype 1), also neutralized most other genotype 1 viruses,
including street isolates (Table 4). Rab-E8 was not neutralizing the
ERA strain, but was also able to neutralize the divergent genotype
5 EBLV-1 strain, which also Rab-H7 neutralized (Table 5). The
neutralization pattern of the different VHH together with the
results from the competition assays with Mab 8-2 indicated
recognition of antigenic site IIa [20] for all but Rab-C12, which
seemed to recognize a different epitope (Figure 4). Although Rab-
E6, Rab-H7, Rab-E8 and Rab-F8 recognized a partially
overlapping epitope, their fine specificity differed, because only
Rab-E8 and Rab-H7 cross-reacted with EBLV-1 (genotype 5)
(Table 5).
Based on the data from the neutralization and the competition
assays, biparatopic and bivalent constructs were generated with a
Gly4/Ser linker of 15 residues. The majority of the tested bivalent
and biparatopic VHH constructs had a significantly higher
neutralizing potency than the corresponding monovalent VHH,
both for CVS-11 and EBLV-1 (Table 5). Exceptions were
constructs containing Rab-C12, bivalent or biparatopic, which
did not, or in some cases, only moderately improve neutralization.
As a bivalent Rab-C12, it neutralized 2 street isolates that were not
neutralized by the monovalent Rab-C12. Compared to the
monovalent VHH, the biparatopic combination Rab-E8/H7
was more than 1,500-fold more potent that the corresponding
VHHs (Rab-E8 and Rab-H7) in neutralizing CVS-11 with an
IC50 of 0.14 nM and about 150-fold better for EBLV-1 (Table 5).
Figure 3. Neutralization and fetuin competition of H5N1-
specific VHH. Monovalent VHH neutralizing Influenza H5N1, A/
Vietnam/1203/04 in a pseudotyped neutralization assay. Neutralization
(geometric mean of duplicates) is expressed in percentage compared to
the virus only and plotted against the concentrations of VHH in molarity
(M) (A). Dilutions of monovalent VHH against Influenza H5 in duplicates,
competing with 10 mg/ml immobilized fetuin for binding to biotiny-
lated H5, expressed as percentage competition. Plotted against
concentrations of VHH in molarity (M). NR is an irrelevant VHH binding
to RSV. Detection of biotinylated H5 as indicated in text. Standard
deviation (SD) indicated by bars (B).
doi:10.1371/journal.pone.0017665.g003
Broad Viral Neutralization by Llama VHH Fragments
PLoS ONE | www.plosone.org 5 April 2011 | Volume 6 | Issue 4 | e17665Fusion of Rab-E6 with Rab-H7 (Rab-E6/H7) improved neutral-
ization of CVS-11 with almost 400-fold and EBLV-1 with more
than 10-fold compared to the monovalent VHH (Table 5). No
synergy was observed when mixing the neutralizing VHH in
equimolar ratio together, only an additive effect (data not shown).
Discussion
In this study, neutralizing VHHs were generated against
trimeric glycoproteins of three different viruses and the potency
and broadness was greatly improved by multimerization of VHH.
The trimeric spike proteins of the three targeted viruses are
functionally different, implying a different mechanism of action for
the multivalent VHH constructs for neutralization of the viruses.
Rabies virus and Influenza virus both use their trimeric spike
proteins, G protein and hemagglutinin, for attachment to the host
cell to allow cell invasion. RSV on the other hand uses its
glycoprotein for attachment to the host cell and then the F protein
for fusion to the host cell membrane after a conformational change
[12,13,14]. Synagis (Palivizumab) blocks the fusion of RSV to its
host cell membrane and is the only clinically used monoclonal
antibody against an infectious disease [21].
Viral neutralizing monovalent VHH, with potencies in the
micromolar range, were generated by immunization of llamas with
recombinant trimeric envelope spike proteins or with (inactivated)
virus from three different viruses, RSV, Rabies virus and highly
pathogenic Influenza H5N1 virus. The single domain nature of
the VHHs allows building of multimeric constructs by fusion of
individual VHHs, either recognizing the same (bi/trivalent) or
different epitopes (biparatopic).
The best improvements in neutralizing potency were observed
for the RSV neutralizing VHH, RSV-D3. When engineered into a
bivalent construct, it was approximately 4,000-fold more potent
than the monovalent fragment, which already had a 2.6-fold better
IC50 than the Fab fragment from Synagis. The bivalent RSV-D3
VHH outperformed the Synagis antibody in the microneutraliza-
tion assay (44-fold better) with IC50 in the picomolar range.
Synagis had a 180-fold better potency than the derived Fab due to
Table 3. Neutralization of Influenza H5N1 virus.
Neutralization of Influenza H5N1 virus IC50 (nM)
a
H5N1 subtype
Infl-C8
(monovalent)
Infl-C8(9GS)2
(bivalent)
Infl-C8(15GS)2
(bivalent)
Infl-C8(10GS)3
(trivalent)
Infl-C8(20GS)3
(trivalent)
A/Vietnam/1194/04 (Clade 1) 75 ,1 ,1 ,11 0
A/Vietnam/1203/04 (Clade 1) 75 ,1 ,1 ,11 0
A/turkey/Turkey/1/05 (Clade 2.2) 120 120 120 3 75
A/Bar-headed goose/Qinghai/1A/05 (Clade 2.2) 50 50 50 7 40
A/Whooping swan/Mongolia/244/05 (Clade 2.2) .150 150 150 18 75
A/Anhui/1/05 (Clade 2.3.4) .1 5 0 9 557 5
A/chicken/Korea/ES/03 (Clade 2.5) No effect ,1 ,1 ,11 5
A/NIBRG-14
b 7 n.d.
c 0.009 0.003 n.d.
aIC50 of VHH neutralizing pseudotyped MLV(H5) virus infection as compared to pseudotyped virus-only control and cells only. IC50 calculated from duplicates as
geometric mean.
bIC50 of VHH in a microneutralization assay on MDCK cells.
cnot determined.
doi:10.1371/journal.pone.0017665.t003
Table 4. Neutralization of Genotype 1 Rabies strains determined by Rapid Fluorescent Focus Inhibition Test (RFFIT) with cell
grown-virus.
Neutralization of Rabies genotype 1 strains IC50 (nM)
ERA (Evelyn-Rotnycki-Abelseth) CB-1 (Chien Beersel) 7 street strains
b
Mab 8-2 22.6
a 13.0 6/7
Rab-F8 94 18.1 7/7
Rab-E8 .3871 18.3 nd
Rab-E6 14.4 4.17 6/7
Rab-H7 25.6 1.05 5/7
Rab-C12 6.63 4.86 4/7
NR1 (anti-RSV) .5956 .5956 0/7
NR4 (anti-RSV) .4839 .4839 0/7
aMean IC50 (nM) of triplicates.
bTissue Culture Infectious Dose 50%, which corresponds with the dilution of the infected brain suspension – VHH mixture which yields 50% infection of neuroblastoma
cells of isolates: 9912CBG (dog, Cambodia), 9147 FRA (fox France), CVS (strain IP13), 9722 POL (raccoon dog, Poland), 8740 THA (Human, Thailand), 070591C (dog, Ivory
coast), 9009 NIG (dog, Niger). Neutralization considered if a minimum of 100-fold reduction of virus infectivity in the brain was observed after preincubation with
antibody (Mab 8-2) or VHH compared to a control VHH (NR4 or NR1 anti-RSV) (#neutralization/#total).
doi:10.1371/journal.pone.0017665.t004
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which competes with and therefore recognizes the same region as
Synagis, must achieve its greatly increased potency by a different
avid interaction. We propose that the bivalent VHH RSV-D3 can
bind both intramolecular to two of the three F-proteins in a spike.
Intramolecular binding has been described for TRAP molecules,
like VEGF TRAP, in which the extracellular domains (ECD) of
VEGF receptors were fused to the Fc of an IgG [22]. VEGF
TRAP forms soluble 1 to 1 complexes by intramolecular binding
of the two ECDs with the dimeric VEGF molecule, giving
picomolar affinities and potencies in bioassays.
Although resistance to Synagis does not yet appear to be a
clinical issue, wider use may increase this potential [23]. Targeting
only one viral epitope with an antibody is a risk, because the virus
can escape relatively easy neutralization by adopting mutations
within the epitope recognized by the mono-specific antibody,
whereas this is more difficult for two or more targeted epitopes.
One way to overcome this is to give cocktails of antibodies. This
has been done for HIV-1 and Rabies and increased neutralization
potency as well as increased cross protection was observed, but
only with an additive effect [24,25]. In this study we demonstrated
for both RSV and Rabies virus that biparatopic VHHs not only
have increased neutralization activity as compared to their
monovalent counterparts, but also display a broader cross subtype
neutralization activity. Although cross subtype protection may be
enhanced by bivalent or trivalent VHH, as was observed for RSV
and Influenza, the most spectacular improvements were achieved
with biparatopic VHH.
A poorly RSV B1 neutralizing VHH (RSV-E4) with high
affinity for the RSV Long strain (subtype A) was combined with a
VHH (RSV-D3) neutralizing the RSV Long strain (subtype A),
but not the RSV B1 strain. The resulting biparatopic VHH
construct had low nanomolar neutralizing potency against RSV
B1 strain than the biparatopic construct, whereas the bivalent
construct of the neutralizing VHH RSV-D3 had a 55-fold lower
Table 5. Neutralization of Lyssavirus determined by Rapid Fluorescent Focus Inhibition Test (RFFIT).
Neutralization of rabies virus IC50 (nM)
a
CVS-11 (genotype 1) EBLV-1 (genotype 5)
sample nM IC50 nM IC50
Mab 8-2 0.25 0.12
Rab-C12
b 7.55 .9529
Rab-E6 13.66 .4913
Rab-H7 191.4 586
Rab-E8 248.9 520
Rab-F8 324.9 .1191
NR (irrelevant anti-RSV) .5956 .5956
Increased potency
c Increased potency
Rab-C122 3.74 2 .4167 .2
Rab-H72 2.09 92
Rab-E82 3.28 76
Rab-F82 1.79 181
Rab-E6/H7 0.26 394 237 .12
Rab-E8/H7 0.14 1572 3.76 147
Rab-E8/C12 3.69 35
Rab-H7/F8 0.33 782 108 .8
NR2 (irrelevant anti-RSV) .725 0
aMean IC50 of triplicates.
bMonovalent and bivalent/biparatopic with 15GS linkers run at two different time points, but standards OIE (canine reference serum) 0.5 IU/ml, WHO human reference
serum 0.5 IU/ml and WHO human reference serum 6.0 IU/ml were included in all experiments as controls.
cPotency compared to monovalent VHH (nM). For the biparatopic constructs, potency increase is based on the mean (nM) of the two monovalent VHH included in the
constructs.
doi:10.1371/journal.pone.0017665.t005
Figure 4. Antibody 8-2 competition of anti-Rabies VHH. Serial
dilutions of VHH against Rabies G protein competing with 4 nM Mab 8-
2 for binding to immobilized G protein. Detection of Mab 8-2 as
indicated in text. Competition is expressed in percentage compared to
the Mab 8-2 bound by immobilized G protein and plotted against the
concentrations of VHH in molarity (M). NR was included at 1 mM only.
The assay was repeated two times and this figure represents one run.
doi:10.1371/journal.pone.0017665.g004
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be an advantage for cross protection. The biparatopic construct
consisting of RSV-D3 and RSV-E4 showed increased neutraliza-
tion potency against the RSV Long strain as compared to the
monovalent VHH. A shorter linker (9 or 15 residues) seemed to be
preferred enforcing intramolecular binding to the D3 and E4
epitopes.
Compared to the monovalent VHHs, combining two neutral-
izers, Rab-E8 and Rab-H7 into biparatopic VHH increased the
potency 1,572-fold against Rabies CVS-11, while the homo-
bivalent constructs had around 20-fold increased potency, with
IC50 similar to the mouse monoclonal antibody 8-2 [20]. The cross
protection against Lyssavirus EBLV-1 was also considerably
improved with this construct, being 147-fold better than the
monovalent building blocks, again showing the power of targeting
two different epitopes on a trimeric viral spike protein.
Influenza virus hemagglutinin is a trimeric spike protein used
for attachment to the host cell receptor. The neutralizing VHH
selected against Influenza H5N1 virus binds to the sialic acid
binding site and thereby inhibits virus attachment to cells as
observed both in the neutralization and Hemagglutination
inhibition assay. Different constructs of IgG directed against
trimeric spikes of Influenza and HIV have been compared, with
IgG being more potent than its monovalent and bivalent derivates
[26,27]. From these studies it can be concluded that size, flexibility
of the linkers and less occlusion effects are important factors to
achieve potent multivalent molecules. VHHs are very small
binding domains (15 kDa), which may allow penetration between
the viral spikes, similar to what has been observed for enzymes
with cleft recognition of the VHH [28]. Moreover, the small size of
VHHs may reduce the risk of occlusions, which was observed for
the larger antibody 4E10 constructs and thereby restricted access
to the desired epitope by Klein et al [27].
For the flexibility, we used the Gly4/Ser linker between VHHs.
This may allow binding and cross linking both intramolecularly to
two of the three units of the viral spikes, intermolecularly to
different spikes on a virus or by agglutination of the viruses.
Furthermore, multimerization of VHHs may inhibit conforma-
tional changes of the viruses, thereby preventing fusion to host cell
membranes. The intrinsic properties of the multimerized VHH
were not investigated in this study, but previous reports on
multimerized VHH show that the constructs are stable and stay
intact in plasma at 37uC for a long time (44 hours) and the half life
can be further improved by including an anti-albumin VHH in the
multimeric construct [29,7]. As reviewed by Saerens et al and
Harmsen et al, the advantages of VHH over monoclonal
antibodies are many such as the rapid tissue penetration,
recognition of hidden antigenic sites, but the lack of effector
functions and the decreased half-life is a disadvantage compared to
monoclonal antibodies [10,30]. Due the small size and high degree
of human sequence homology of the frameworks of the VHH
humanization processes to avoid immunogenicity seems straight-
forward and VHH with long serum half-life against RANKL has
already successfully passed phase I clinical trial (Ablynx NV).
This is the first report of multivalent VHHs against trimeric
spikes of virus causing infections in humans with greatly increased
neutralization and cross protection potency.
Materials and Methods
Generation of viral specific Llama VHH
All animal experiments were conducted with the approval of the
Ethical committee of the Faculty of Veterinary Medicine
(University of Ghent, Belgium, EC number is 2006/076) and
Ethical Committee of the IPH and the Veterinary and
Agrochemical Research Centre (VAR, Brussels, Belgium, IPH
authorization nr. LA1230177, advice nr. 070515-04). The animal
immunization protocol is based upon on the guidelines available
for Guanaco and Vicun ˜a (llama species) as described in the
Ministerial Decree of 05.03.1999 (for zoo animals) and the
guidelines for farm animals used as laboratory animals described
in Appendix A of the European convention for the protection of
vertebrate animals used for experimental and other scientific
purposes, from the European Treaty Series (ETS) 123.
Immunizations of llamas and library constructions were
performed as described previously [3,8] with six weekly injections
for RSV and H5N1 and collection of 150 ml blood for isolation of
RNA from the peripheral blood lymphocytes seven weeks after the
initial immunization, resulting in two libraries for each viral target.
The rabies immunizations were performed five times distributed
over 57 days. The antigens used for immunizations were: trimeric
RSV FTM- protein (membrane anchor less form of the fusion
protein, 70 kDa as monomeric protein [31]), H5N1 Hemagglu-
tinin (H5, A/Vietnam/1203/2004, Protein Sciences Corporation)
or Inactivated Rabies Vaccine Me ´rieux HDCV (genotype 1,
Wistar Pitman Moore strain, Sanofi Pasteur MSD). Of the RSV
FTM- protein and of the H5 hemagglutinin, 40 mg were used for
the first two doses and 20 mg for the following four doses.
RNA isolation and library constructions were performed as
previously described amplifying the VHH genes and ligate them
into a phagemid vector for display on phage resulting in libraries
of size around 10
8 [8].
Selections were performed on immobilized recombinant
trimeric proteins and unspecific and competitive elutions using
monoclonal antibodies were performed as previously described
[3]. SynagisH (PalivizuMab, MedImmune Inc., humanized
monoclonal IgG1k antibody [16]) was used for competitive elution
of RSV FTM- protein specific VHH. Selections for Rabies
glycoprotein (G protein) specific VHH were performed on 8 wells
strips pre-coated with G protein from genotype 1, PV (Pasteur)
strain (Platelia II Rabies plates, Bio-Rad Laboratories). Specific
elutions were performed using a Rabies specific mouse monoclonal
IgG2a 8-2 (EBL-1, genotype 5 specific) [20]. For all three viruses,
unspecific elutions of bound phage using trypsin were performed.
Eluted phage were used to infect exponentially growing E. coli
TG1 that were plated on Luria broth (LB) agar plates containing
2% (w/v) glucose and 100 mg/ml ampicillin. Periplasmic extracts
containing VHH were prepared according to standard protocols
and selected VHH were sent for sequencing.
Binding ELISA
To determine binding specificity to the viral coat proteins,
periplasmic extracts and purified VHH were tested in ELISA
binding assays. One hundred ng/ml RSV FTM- protein, 0.5 mg/
well RSV (Hytest, Turku, Finland) or 200 ng/ml Hemagglutinin
H5 were immobilized on Nunc Maxisorp microtiter plates in PBS
over night at 4uC. Rabies G protein pre-coated 8-well strips from
BioRad were used for binding studies of Rabies specific VHH.
Free binding sites were blocked using 4% skimmed milk or 1%
casein in PBS (w/v) for 1–2 h at RT. Ten ml of VHH containing
periplasmic fractions or dilutions of purified VHH in 100 ml were
added to the blocked wells and allowed to bind for 1 h at RT.
After incubation and washing steps, 1/2,000 rabbit anti-llama
antibody (a kind gift from Unilever Research) and then 1/10,000
HRP-conjugated goat anti-rabbit antibody (DAKO) or 1/2,000
mouse anti-c-myc antibody and then 1/10,000 HRP-conjugated
donkey anti-mouse antibody were added to detect binding of the
VHH containing periplasmic fractions or purified VHH. Both
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developed with o-phenylenediamine (OPD) or TMB in the
presence of H2O2 and the reactions were stopped with 1M
H2SO4. Absorptions at 490 nm (OPD) or 450 nm (TMB) were
measured using a microtiter plate reader. Competition was
determined based on lower optical density (OD) values compared
to controls having received no VHH or irrelevant VHH. The
assays were repeated at least three times, but with some variation
in secondary antibodies and read outs, confirming the binding
pattern of the VHH.
ELISA based competition assays
Competition assays were used for further characterization of the
different anti-viral VHH.
For RSV specific VHH, RSV FTM- (200 ng/well) were
immobilized on Nunc Maxisorp microtiter plates in PBS over
night at 4uC. Free binding sites were blocked using 4% skimmed
milk or 2% bovine serum albuminin PBS (w/v).Ten or 20 ml VHH
containing periplasmic fractions or dilutions of purified VHH were
added together with 0.67 nM Synagis Mab, 3 nM Synagis Fab
(HA-tagged, a kind gift from Ablynx NV) or 3 nM 101F Fab (HA-
tagged, a kind gift from Ablynx NV). After incubation and a wash
step, antibody binding was revealed using HRP-conjugated goat
antibody specific for human Fc for Synagis Mab, a mouse antibody
specific for HA-tag (Zymed laboratories) in combination with a
HRP-conjugated rabbit antibody specific for mouse antibodies
(Dako BV) for detection of Synagis Fab and 101F Fab.
For Influenza H5 specific VHH, fetuin from fetal calf serum
(10 mg/well, Sigma-Aldrich) was immobilized on Nunc Maxisorp
microtiter plates in PBS over night at 4uC. 100 ng/ml biotinylated
H5 A/Vietnam/1194/04 (5 molar excess of sulfo-NHS-biotin
incubated with the Influenza H5 for 30 min at RT before dialysis
against PBS) was added to the coated wells and incubated with 10
or 20 ml of VHH containing periplasmic fractions or dilutions of
purified VHH. After incubation for 1 h and washing steps, 1/
5,000 diluted HRP-conjugated streptavidin was added for
detection of biotinylated H5 and incubated for 1 h at RT.
For Rabies competition assays, Rabies G protein pre-coated 8-
well strips from BioRad were used. Free binding sites were blocked
using 4% skimmed milk or 2% bovine serum albumin in PBS (w/
v). Next, 4 nM mouse IgG2a monoclonal 8-2 was added to the
coated wells and incubated with 10 or 20 ml of VHH containing
periplasmic fractions or dilutions of purified VHH. Control
periplasmic fractions or VHH selected against other viral coat
proteins were included. After incubation and a wash step, antibody
binding was revealed using a HRP conjugated donkey antibody
specific for mouse antibodies for detection of mouse monoclonal
IgG2a 8-2.
For all viral competition assays, peroxidase activity was
developed with o-phenylenediamine (OPD) or TMB in the
presence of H2O2 and the reactions were stopped with 1M
H2SO4. Absorptions at 490 nm (OPD) or 450 nm (TMB) were
measured using a microtiter plate reader. Competition was
determined based on lower optical density (OD) values compared
to controls having received no VHH or irrelevant VHH.
Reactivity of VHH against RSV escape mutants
The isolation and characterization of RSV escape mutants has
been described [15]. Hep-2 cells were infected with the different
viruses at m.o.i of 0.1 pfu/cell, harvested 72 h later, when
cytopathic effect was maximal, and extracts were made as
described [32]. Dilutions of the extracts were tested by ELISA
with a polyclonal serum against F [32] to normalize the amount of
F protein in each extract. Then, an equal amount of F protein
from the different mutants was tested for reactivity with non-
saturating amounts of VHHs, 0.2 mg/ml in ELISA. Absorbance
results were normalized for reactivity on the reference virus strain
(Long wild type) strain as well as on the control VHH RSV-C7.
Surface Plasmon resonance for affinity measurements
For affinity measurements of VHH against Influenza H5 and
epitope mapping, 2,000 Resonance units (RU) of Influenza H5
was coupled on a Sensorchip CM5 in 10 mM sodium acetate
pH 5.5 and immobilized by aminecoupling (aminecoupling kit,
BIAcore) and run in a BIAcore 3000. Dilutions of the VHH were
added at concentrations 12.5–250 nM and run over a reference
flow channel with no H5 and run in parallell over the H5 coupled
flow channel at a flow rate of 30 ml/min. One mM NaOH was
used for regeneration of the chip.
Affinity measurements of VHH against RSV FTM- were
performed in a BIAcore T1000. Around 400 RU RSV FTM-
were coupled in 10 mM sodium acetate buffer pH 4.5 and
immobilized by aminecoupling. Dilutions of the VHH were added
at concentrations 1–243 nM for the VHH and 0.5–500 nM for
the Synagis Mab and Fab and run over a reference flow channel
with no RSV FTM- and run in parallell over the RSV FTM-
coupled flow channel at a flow rate of 45 ml/min. Onehundred
mM HCl was used for regeneration of the chip.
Evaluation of association rate constants (kon), dissociation rate
constants (koff) and equilibrium dissociation constants (KD=kon/koff)
was performed by fitting a 1:1 interaction model (Langmuir
binding model), removing the background from the reference flow
channel by Biacore T100 software v1.1 for RSV evaluations and
Biacore 3000 Software v4.1 for the Influenza H5 evaluations.
Re-cloning and purification of monovalent and
multimeric VHH
The encoding sequences for selected VHH were re-cloned in
expression vectors containing C-terminal c-myc and His6 tags,
pAX051 or pAX100. Generation of multimeric constructs were
performed as previously described [8]. Briefly, bivalent or
biparatopic constructs connected by Gly4/Ser linkers of different
lengths and composition were generated by separate PCR
reactions (one for the N-terminal and one for the C-terminal
VHH subunit and for trivalent constructs, one extra PCR reaction
for the middle VHH subunit) using different sets of primers
encompassing parts of the linker and restriction sites SfiI in the N-
terminal, BstEII in the C-terminal and BspEI, for re-cloning into
the expression vectors. The Gly/Ser linkers were ranging from 9
(G4SG3S) to 35 (G4S)7 residues. The biparatopic constructs (fusion
of two different VHH) were done in both directions.
After induction of a logarithmic phase culture with 1 mM
isopropyl-b-D-thiogalactopyranoside (IPTG) for expression of
His6-tagged proteins, VHH were purified from the periplasmic
fraction by Immobilized affinity chromatography (IMAC) using
Talon metalaffinity resin (BD Biosciences) and washed and eluted
according to the manufacturer’s protocol. The eluted VHH were
extensively dialyzed against PBS and stored at 220uC in small
aliquots.
To check the size and purity of the purified VHH fragments,
0.5–1 mg was run on 15% SDS-PAGE under reducing conditions
and stained with Coomassie Brilliant Blue (CBB).
RSV micro neutralization assay
The potency of purified VHH in neutralization of different type
A and B RSV strains was tested by the in vitro micro neutralization
assay. Viral stocks of RSV Long strain (originally isolated in
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prepared in HEp-2 cells and subsequently titrated to determine the
optimal infectious dose (1–3 pfu/cell) for use in the micro
neutralization assay. HEp-2 cells were seeded at a density of
1.5610
4 cells/well into 96-well plates in DMEM medium
containing 10% fetal calf serum (FCS) supplemented with
penicillin and streptomycin (100 U/ml and 100 mg/ml, respec-
tively) and incubated for 24 h at 37uC in a 5% CO2 atmosphere.
The RSV strains were pre-incubated with serial dilutions of
purified VHH in a total volume of 50 ml for 30 min at 37uC. The
medium of the HEp-2 cells was replaced with the premix to allow
infection for 2 h, after which 0.1 ml of assay medium was added.
Cells were incubated for additional 72 h at 37uC in a 5% CO2
atmosphere, after which cells were fixed with 80% cold acetone
(Sigma-Aldrich) in PBS (100 ml/well) for 20 min at 4uC and left to
dry completely. The presence of the F-protein on the cell surface
was detected in an ELISA type assay. Fixed HEp-2 cells were
blocked with 2% BSA solution in PBS for 1 h at RT, incubated
with for 1 h with polyclonal rabbit serum specific for F-protein or
monoclonal antibody Synagis (2 mg/ml). HRP conjugated goat
antibody specific for rabbit or HRP conjugated goat antibody
specific for Human IgG (Fcc fragment, Jackson ImmunoResearch)
were used for detection, after which the ELISA was developed
according to standard procedures. RSV-D3, Synagis Mab, Synagis
Fab and irrelevant VHH were included as controls. The
percentage competition was calculated based on controls receiving
irrelevant VHH (0%) and no virus (100%) using GraphPad Prism
and non-linear regression curve fit. All experiments were repeated
two times.
MLV(H5) pseudotype neutralization assay
The neutralizing capacity of VHH against Influenza H5 was
evaluated in the MLV(H5) Pseudotyped neutralization assay
described by Temperton et al, 2007 [16]. The pseudotyped virus
as used in this study were expressing the Influenza hemagglutinin
H5 of A/Vietnam/1194/04 (Clade 1), A/Vietnam/1203/04
(Clade 1, a kind gift from Barbara Capecchi, Novartis Vaccines,
Siena), A/turkey/Turkey/1/05 (Clade 2.2, a kind gift from Yipu
Lin, MRC National Institute for Medical research, Mill Hill, UK),
A/Anhui/1/05 (Clade 2.3.4, a kind gift from Barbara Capecchi),
A/Bar-headed goose/Qinghai/1A/05 (Clade 2.2), A/Whooping
swan/Mongolia/244/05 (Clade 2.2, a kind gift from Barbara
Capecchi) and A/chicken/Korea/ES/03 (Clade 2.5, a kind gift
from Chung Kang, Korea CDC).
Briefly, purified VHH were twofold serially diluted in culture
medium, and mixed with MLV (H5) virions (10,000 RLU for
Luciferase) at a 1:1 v/v ratio. After incubation at 37uC for 1 h,
1610
4 293T cells were added to each well of a 96-well flat-
bottomed plate. Relative light units (RLU) for Luc were evaluated
48 h later by luminometry using the Promega Bright-Glo system
(Promega) according to the manufacturer’s instructions. The
neutralizing VHH titers were determined as the concentration
resulting in a 50% reduction of infection (as measured by marker
gene transfer) compared with a pseudotype virus only control. For
Luc, titers ,100 were designated negative.
All samples were run in duplicates and the geometric mean was
calculated. A standard serum (sheep H5 reference sera from
NIBSC) was always included.
Influenza microneutralization assay
The assay was based on the protocol recommended by WHO
(2002) and adapted as follows: Two-fold serial dilutions of VHHs
(initial concentration 5 mM) were mixed 1:1 with 50 ml of NIBRG-
14 (H5N1), PR8 (H1N1) or X47 (H3N2) virus and incubated at
37uC for 2 h after which the mixture was transferred to MDCK
cell monolayers and incubated for 18 to 22 h at 37uC in virus
growth medium with trypsin. The amount of virus used in the
assays was 100 tissue culture infectious doses as determined by the
same NP (nucleoprotein)-ELISA used to determine microneutra-
lization efficacy. Anti-NP antibody was obtained through the NIH
Biodefense and Emerging Infections Research Resources Repos-
itory, NIAID, NIH: Antisera Panel to Isolated Antigens of
Influenza Virus, NR-10208. After fixation of the cells with
ethanol:acetone (1:1) for 20 min at 220uC, influenza virus growth
was detected by an antibody specific for NP. The fixed plates were
washed with PBS containing 0.05% Tween 20. A goat antibody
specific for NP was diluted 3,000-fold in PBS containing 1%
bovine serum albumin and 0.1% Tween 20 and incubated for 1 h.
Horseradish peroxidase-labelled goat antibody was diluted 4,000-
fold and incubated for 1 h at room temperature. One hundred
microliters of freshly prepared HRP substrate was added to each
well, and the plates were incubated at room temperature for
approximately 5 min. The reaction was stopped with an equal
volume of 1 N sulfuric acid. The absorbance was measured at
450 nm and 595 nm with an iMark microplate reader (Bio-rad).
Hemagglutination Inhibition assay
The assay was based on the protocol from WHO (http://www.
who.int/vaccine_research/diseases/influenza/WHO_manual_on_
animal-diagnosis_and_surveillance_2002_5.pdf). After determining
the optimal HA units for the Influenza H5N1, NIBRG-14 carrying
the A/Vietnam/1194/2004, two-fold dilutions of purified VHH
(initial concentration 5 mM) were added to 4 HA units of NIBRG-
14 and 1% chicken red blood cells (RBC) in PBS (total volume of
25 ml) in 96-well V-shaped microtiter plates. The minimal
inhibitory concentration of hemagglutination for the different
VHH constructs compared to control VHH was determined.
Rabies virus neutralization assays
Two assays were used to examine virus neutralization,
depending on whether the virus was propagated in cell culture
or in the brain of mice upon intracerebral inoculation. Cell
culture-grown viruses were examined in the Rapid Fluorescent
Focus Inhibition Test (RFFIT) and brain-grown viruses in an
alternative infection assay with neuroblastoma N2a cells.
Neutralizing potency against 4 cell culture-grown viruses was
examined by RFFIT. CVS-11 (Challenge Virus Standard-11, The
American Type Culture Collection (ATCC) reference VR-959) is
a virulent genotype 1 strain, which is used as the reference
laboratory strain in the RFFIT. ERA (Evelyn-Rotnycki-Abelseth)
is an attenuated genotype 1 virus which is used as an oral vaccine
for immunization of wildlife (ATCC VR322). CB-1 (Chien
Beersel) is a virulent genotype 1 isolate from the brain of a rabid
dog from Morocco [33]. The EBLV-1 (European Bat Lyssavirus-
1) strain 8919FRA is a virulent genotype 5 strain, which was
isolated from an Eptesicus serotinus bat in France [34] and kindly
provided by Dr. L. Dacheux from the Pasteur Institute of Paris.
The viral stocks were grown in Baby Hamster Kidney-21 cells
(BHK-21) cells, except for CB-1, which was grown in neuroblas-
toma N2a cells. The lysates of infected cell cultures were
centrifuged at 20,000g for 20 min at 4uC and supernatants were
stored at 280uC.
The RFFIT was performed according to the Manual of
Diagnostic Tests and Vaccines for Terrestrial Animals (Office
International des Epizooties, 2008). Briefly, susceptible cells
(BHK-21 for CVS-11, ERA, EBLV-1 and neuroblastoma N2a
cells for CB-1) were infected with a standard amount of virus after
pre-incubation with VHH. The virus neutralization was quantified
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staining with fluorescein isothiocyanate (FITC)-coupled specific
rabies monoclonal antibodies (Fujirebio Diagnostics, Inc.). In each
test, one OIE canine reference serum, containing 0.50 IU/ml, and
two WHO human reference sera, containing respectively
0.50 IU/ml and 6.00 IU/ml, were included as controls of the
assays. (International Units (IU)/ml in reference to ‘‘The Second
International standard for Anti-Rabies Immunoglobulin’’ pur-
chased from the United Kingdom National Institute for Biological
Standards and Control.) All experiments were performed in
triplicates and the mean was calculated. Neutralizing potency of
the VHH was expressed as mean nM IC50 (VHH concentration
needed to neutralize 50% of 10
3 TCID50 of CVS-11 on BHK
cells). According to the WHO convention, a serum titer of
0.50 IU/ml is protective in vivo. Neutralizing potency of the other
strains was defined in Equivalent Units (EU)/ml, which corre-
spond closely to IU/ml. Mab 8-2 is a mouse monoclonal IgG2a
raised against the rabies glycoprotein G [20].
Seven brain-grown genotype 1 viruses were tested in a
neuroblastoma N2a infection assay [35]. All viruses were provided
by Dr. L. Dacheux from the Pasteur Institute of Paris. Six viruses
were wild isolates, among which an isolate from a dog from
Cambodia (9912CBG, accession nr. EU086169/EU086132), a fox
from France (9147FRA, accession nr. EU293115), a raccoon dog
from Poland (9722POL), a human patient from Thailand
(8740THA), a dog from the Ivory Coast (07059IC, accession nr.
EU853615/FJ545659) and a dog from Niger (9009NIG, accession
nr. EU853646). One virus was the laboratory strain CVS IP13.
Briefly, suspensions of infected brain tissues (0.1% w/v) were
prepared in cell culture medium at 4uC. Ten-fold dilutions of the
infected brain suspensions were pre-incubated with about 0.2 mM
of VHH for 90 min at 37uC and 5% CO2. Then, susceptible
neuroblastoma N2a cells were added to the mix. Two days later,
the number of nucleocapsid-positive cells was counted upon
staining with FITC-coupled specific rabies monoclonal antibodies
(Fujirebio Diagnostics, Inc.). Neutralization was defined as a
minimum 100-fold reduction of virus infectivity in the brain after
preincubation with antibody (Mab 8-2) or VHH compared to a
control VHH (NR4 against RSV).
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